These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

815 related items for PubMed ID: 31227464

  • 21. A pictorial view on false positive findings of 68Ga-PSMA-11 PET/CT and their prognostic value in patients with prostate carcinoma after radical prostatectomy and undetectable PSA values.
    Dancheva Z, Chausheva S, Stoeva T, Dyankova M, Yordanova T, Chaushev B, Marinov R, Nikolov V, Abushev P, Todorov G, Dimitrova E, Klisarova A, Anakievski D.
    Hell J Nucl Med; 2024; 27(1):16-26. PubMed ID: 38629815
    [Abstract] [Full Text] [Related]

  • 22. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    Timm B, Farag M, Liodakis P, Angus D, Lim Joon D, Bolton D.
    BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332
    [Abstract] [Full Text] [Related]

  • 23. The impact of [68Ga]PSMA I&T PET/CT on radiotherapy planning in patients with prostate cancer.
    Frenzel T, Tienken M, Abel M, Berliner C, Klutmann S, Beyersdorff D, Schwarz R, Krüll A, Bannas P.
    Strahlenther Onkol; 2018 Jul; 194(7):646-654. PubMed ID: 29572670
    [Abstract] [Full Text] [Related]

  • 24. Diagnostic Performance of 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography to Monitor Treatment Response in Patients with Metastatic Prostate Cancer: The Concordance Between Biochemical Response and Prostate-specific Membrane Antigen Results.
    Esen B, Seymen H, Tarim K, Koseoglu E, Bolukbasi Y, Falay O, Selçukbiricik F, Molinas Mandel N, Kordan Y, Demirkol MO, Tilki D, Esen T.
    Eur Urol Focus; 2023 Sep; 9(5):832-837. PubMed ID: 37032281
    [Abstract] [Full Text] [Related]

  • 25. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [Abstract] [Full Text] [Related]

  • 26. [89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
    Rosar F, Burgard C, Larsen E, Khreish F, Marlowe RJ, Schaefer-Schuler A, Maus S, Petto S, Bartholomä M, Ezziddin S.
    Cancer Imaging; 2024 Feb 22; 24(1):27. PubMed ID: 38389092
    [Abstract] [Full Text] [Related]

  • 27. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
    Calderoni L, Maietti E, Farolfi A, Mei R, Louie KS, Groaning M, Fanti S.
    J Nucl Med; 2023 Jun 22; 64(6):910-917. PubMed ID: 36635087
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Findings in 1,123 Men with Preoperative 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Implications for the Diagnosis and Management of Prostate Cancer.
    Raveenthiran S, Yaxley WJ, Franklin T, Coughlin G, Roberts M, Gianduzzo T, Kua B, Samaratunga H, Delahunt B, Egevad L, Wong D, McEwan L, Brown N, Parkinson R, Esler R, Yaxley JW.
    J Urol; 2022 Mar 22; 207(3):573-580. PubMed ID: 34694140
    [Abstract] [Full Text] [Related]

  • 30. Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence.
    Bianchi L, Castellucci P, Farolfi A, Droghetti M, Artigas C, Leite J, Corona P, Shagera QA, Moreira R, González C, Queiroz M, de Galiza Barbosa F, Schiavina R, Deandreis D, Fanti S, Ceci F.
    Eur Urol Oncol; 2023 Feb 22; 6(1):41-48. PubMed ID: 34933814
    [Abstract] [Full Text] [Related]

  • 31. The role of histopathological and biochemical parameters for predicting metastatic disease on 68 Ga-PSMA-11 PET in prostate cancer.
    Aydos U, Çetin S, Akdemir ÜÖ, Budak FÇ, Ateş SG, Koparal MY, Gönül İI, Gülbahar Ö, Sözen S, Atay LÖ.
    Prostate; 2021 Dec 22; 81(16):1337-1348. PubMed ID: 34516677
    [Abstract] [Full Text] [Related]

  • 32. Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology.
    Kalapara AA, Ballok ZE, Ramdave S, O'Sullivan R, Ryan A, Konety B, Grummet JP, Frydenberg M.
    Eur Urol Oncol; 2022 Jun 22; 5(3):314-320. PubMed ID: 33741337
    [Abstract] [Full Text] [Related]

  • 33. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT).
    Heetman JG, Lavalaye J, Polm PD, Soeterik TFW, Wever L, Paulino Pereira LJ, van der Hoeven EJRJ, van Melick HHE, van den Bergh RCN.
    Eur Urol Oncol; 2024 Apr 22; 7(2):204-210. PubMed ID: 37296065
    [Abstract] [Full Text] [Related]

  • 34. PSMA-11 PET/CT for Detection of Recurrent Prostate Cancer in Patients With Negative Choline PET/CT.
    Pinot F, Le Pennec R, Abgral R, Blanc-Béguin F, Hennebicq S, Schick U, Valeri A, Fournier G, Le Roux PY, Salaun PY, Robin P.
    Clin Genitourin Cancer; 2023 Apr 22; 21(2):248-257. PubMed ID: 36658064
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Evaluation of the clinical use of PET/CT with 68Ga-PSMA for the assessment of biochemical recurrence of low or intermediate-risk prostate cancer.
    Ribeiro AMB, Lima ENP, Zequi SC.
    Urol Oncol; 2021 Jan 22; 39(1):73.e9-73.e18. PubMed ID: 32861620
    [Abstract] [Full Text] [Related]

  • 37. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.
    De Man K, Van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, Piron S, Lumen N, Decaestecker K, Fonteyne V, Delrue L, De Vos F, Ost P.
    Eur Urol; 2022 Nov 22; 82(5):501-509. PubMed ID: 35690515
    [Abstract] [Full Text] [Related]

  • 38. An Update on the Role of mpMRI and 68Ga-PSMA PET Imaging in Primary and Recurrent Prostate Cancer.
    Bagheri H, Mahdavi SR, Geramifar P, Neshasteh-Riz A, Sajadi Rad M, Dadgar H, Arabi H, Zaidi H.
    Clin Genitourin Cancer; 2024 Jun 22; 22(3):102076. PubMed ID: 38593599
    [Abstract] [Full Text] [Related]

  • 39. Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology.
    Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M.
    BJU Int; 2020 Jul 22; 126(1):83-90. PubMed ID: 31260602
    [Abstract] [Full Text] [Related]

  • 40. Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study).
    Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, Novruzov F, Lengana T, Granados C, Kumar R, Rangarajan V, Al-Ibraheem A, Hourani M, Ali NS, Ahmad A, Keidar Z, Küçük O, Elboga U, Bogoni M, Paez D.
    J Nucl Med; 2022 Feb 22; 63(2):240-247. PubMed ID: 34215674
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.